Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885490300> ?p ?o ?g. }
- W2885490300 endingPage "74" @default.
- W2885490300 startingPage "68" @default.
- W2885490300 abstract "Introduction Several real-world experience (RWE) studies with vedolizumab (VDZ) for induction of remission in inflammatory bowel diseases (IBD) have been published; however, long-term RWE data is scarce. Aims To describe the effectiveness and safety of VDZ in maintenance treatment of IBD. Methods A multicenter retrospective national study. The primary outcome of was clinical response at week 52; main secondary aims included clinical remission at week 52, rates of secondary loss of response and treatment discontinuation. Results We included 193 (133—CD; 60—UC) patients from 9 Israeli IBD centers. At week 52, response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission; 71 (53.3%) discontinued treatment or did not respond. For UC, response at week 52 was observed in 27/60 (45%), including 20 (33%) in clinical remission; 33 (55%) discontinued treatment or did not respond. Secondary non-response by week 52 occurred in 19.4% and 23.5% of week 14 responders in CD and UC, respectively. Week 14 response was associated with treatment continuation at week 52: no predictors of secondary loss of response were identified. Summary VDZ is safe and effective for maintenance of response and remission in IBD; week 14 response is positively associated with long-term response in both UC and CD." @default.
- W2885490300 created "2018-08-22" @default.
- W2885490300 creator A5001233161 @default.
- W2885490300 creator A5005564075 @default.
- W2885490300 creator A5012027995 @default.
- W2885490300 creator A5024970715 @default.
- W2885490300 creator A5029273084 @default.
- W2885490300 creator A5030745208 @default.
- W2885490300 creator A5033531513 @default.
- W2885490300 creator A5033989831 @default.
- W2885490300 creator A5037885531 @default.
- W2885490300 creator A5038943461 @default.
- W2885490300 creator A5042847255 @default.
- W2885490300 creator A5047907008 @default.
- W2885490300 creator A5062860652 @default.
- W2885490300 creator A5065046461 @default.
- W2885490300 creator A5069738170 @default.
- W2885490300 creator A5070365540 @default.
- W2885490300 creator A5079488262 @default.
- W2885490300 creator A5080002704 @default.
- W2885490300 date "2019-01-01" @default.
- W2885490300 modified "2023-10-18" @default.
- W2885490300 title "Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience" @default.
- W2885490300 cites W1147871078 @default.
- W2885490300 cites W2011837830 @default.
- W2885490300 cites W2031193040 @default.
- W2885490300 cites W2063418390 @default.
- W2885490300 cites W2077531651 @default.
- W2885490300 cites W2135975326 @default.
- W2885490300 cites W2162805528 @default.
- W2885490300 cites W2215084273 @default.
- W2885490300 cites W2326348131 @default.
- W2885490300 cites W2330470789 @default.
- W2885490300 cites W2427633307 @default.
- W2885490300 cites W2460337359 @default.
- W2885490300 cites W2529617706 @default.
- W2885490300 cites W2544630376 @default.
- W2885490300 cites W2549232442 @default.
- W2885490300 cites W2586374020 @default.
- W2885490300 cites W2602331900 @default.
- W2885490300 cites W2603062471 @default.
- W2885490300 cites W2765680011 @default.
- W2885490300 cites W2809894743 @default.
- W2885490300 doi "https://doi.org/10.1016/j.dld.2018.07.040" @default.
- W2885490300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30172649" @default.
- W2885490300 hasPublicationYear "2019" @default.
- W2885490300 type Work @default.
- W2885490300 sameAs 2885490300 @default.
- W2885490300 citedByCount "23" @default.
- W2885490300 countsByYear W28854903002019 @default.
- W2885490300 countsByYear W28854903002020 @default.
- W2885490300 countsByYear W28854903002021 @default.
- W2885490300 countsByYear W28854903002022 @default.
- W2885490300 countsByYear W28854903002023 @default.
- W2885490300 crossrefType "journal-article" @default.
- W2885490300 hasAuthorship W2885490300A5001233161 @default.
- W2885490300 hasAuthorship W2885490300A5005564075 @default.
- W2885490300 hasAuthorship W2885490300A5012027995 @default.
- W2885490300 hasAuthorship W2885490300A5024970715 @default.
- W2885490300 hasAuthorship W2885490300A5029273084 @default.
- W2885490300 hasAuthorship W2885490300A5030745208 @default.
- W2885490300 hasAuthorship W2885490300A5033531513 @default.
- W2885490300 hasAuthorship W2885490300A5033989831 @default.
- W2885490300 hasAuthorship W2885490300A5037885531 @default.
- W2885490300 hasAuthorship W2885490300A5038943461 @default.
- W2885490300 hasAuthorship W2885490300A5042847255 @default.
- W2885490300 hasAuthorship W2885490300A5047907008 @default.
- W2885490300 hasAuthorship W2885490300A5062860652 @default.
- W2885490300 hasAuthorship W2885490300A5065046461 @default.
- W2885490300 hasAuthorship W2885490300A5069738170 @default.
- W2885490300 hasAuthorship W2885490300A5070365540 @default.
- W2885490300 hasAuthorship W2885490300A5079488262 @default.
- W2885490300 hasAuthorship W2885490300A5080002704 @default.
- W2885490300 hasConcept C126322002 @default.
- W2885490300 hasConcept C167135981 @default.
- W2885490300 hasConcept C197934379 @default.
- W2885490300 hasConcept C2776207728 @default.
- W2885490300 hasConcept C2776694085 @default.
- W2885490300 hasConcept C2776914184 @default.
- W2885490300 hasConcept C2778260677 @default.
- W2885490300 hasConcept C2778283404 @default.
- W2885490300 hasConcept C2778715236 @default.
- W2885490300 hasConcept C2779134260 @default.
- W2885490300 hasConcept C2780479503 @default.
- W2885490300 hasConcept C3020196126 @default.
- W2885490300 hasConcept C71924100 @default.
- W2885490300 hasConcept C90924648 @default.
- W2885490300 hasConceptScore W2885490300C126322002 @default.
- W2885490300 hasConceptScore W2885490300C167135981 @default.
- W2885490300 hasConceptScore W2885490300C197934379 @default.
- W2885490300 hasConceptScore W2885490300C2776207728 @default.
- W2885490300 hasConceptScore W2885490300C2776694085 @default.
- W2885490300 hasConceptScore W2885490300C2776914184 @default.
- W2885490300 hasConceptScore W2885490300C2778260677 @default.
- W2885490300 hasConceptScore W2885490300C2778283404 @default.
- W2885490300 hasConceptScore W2885490300C2778715236 @default.
- W2885490300 hasConceptScore W2885490300C2779134260 @default.
- W2885490300 hasConceptScore W2885490300C2780479503 @default.